Gocatamig
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Gocatamig
- gocatamig
- Gocatamig
- gocatamig [INN]
- GOCATAMIG [USAN]
- gocatamig inn
- gocatamig usan
- ig single chain scfvhl vh vh 1 505 scfvhl anti cd3e 1 149 vh musmus homsap mus musculus ighv10 1 02 89 9 ighd ighj3 01 100 homo sapiens ighv3 73 01 85 0 ighd ighj5 01 100 cdr imgt 8 10 16 26 33 51 60 99 114 1 125 15 mer tris tetraglycylseryl linker 126 140 v lambda homo sapiens iglv7 43 01 86 2 iglj3 02 100 cdr imgt 9 3 9 166 174 192 194 231 239 141 249 9 mer tetraglycyl seryltriglycyl seryl linker 250 258 vh anti alb homo sapiens ighv3 23 04 88 5 ighd ighj1 01 81 8 w118 s 363 g119 s 364 cdr imgt 8 8 8 284 291 309 316 355 362 259 373 9 mer tetraglycyl seryl triglycyl seryl linker 374 382 vh anti dll3 vicpac homsap vicugna pacos ighv3s53 01 77 3 ighd ighj5 01 100 homo sapiens ighv3 7 01 77 1 ighd ighj4 01 100 cdr imgt 8 7 11 408 415 433 440 478 488 383 499 hexahistidine tag 500 505 produced in chinese hamster ovary cho cells cell line cho dg44 lacking the enzyme dihydrofolate reductase dhfr non glycosylated
- IG single chain scFvhl-VH-VH' (1-505) [scFvhl anti-CD3E (1-149) [VH Musmus/Homsap (Mus musculus IGHV10-1*02 (89.9%) -(IGHD) -IGHJ3*01 (100%)/Homo sapiens IGHV3-73*01 (85.0%) -(IGHD) -IGHJ5*01 (100%), CDR-IMGT [8.10.16] (26-33.51-60.99-114)) (1-125) -15-mer-tris(tetraglycylseryl) linker (126-140) -V-LAMBDA (Homo sapiens IGLV7-43*01 (86.2%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (166-174.192-194.231-239)) (141-249)] -9-mer-tetraglycyl-seryltriglycyl-seryl linker (250-258) -VH anti-ALB (Homo sapiens IGHV3-23*04 (88.5%) -(IGHD) -IGHJ1*01 (81.8%) W118>S (363), G119>S (364), CDR-IMGT [8.8.8] (284-291.309-316.355-362)) (259-373) -9-mer-tetraglycyl-seryl-triglycyl-seryl linker (374-382) -VH anti-DLL3 Vicpac /Homsap (Vicugna pacos IGHV3S53*01 (77.3%) -(IGHD) -IGHJ5*01 (100%)/Homo sapiens IGHV3-7*01 (77.1%) -(IGHD) -IGHJ4*01 (100%), (CDR-IMGT [8.7.11] (408-415.433-440.478-488)) (383-499) -hexahistidine tag (500-505)], produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, lacking the enzyme dihydrofolate reductase (DHFR), non-glycosylated
- immunoglobulin single chain scfvhl vh vh anti homo sapiens cd3e cd3 epsilon leu 4 anti homo sapiens alb albumin human serum albumin hsa and anti homo sapiens dll3 delta like ligand 3 delta like canonical notch ligand 3 trispecific
- immunoglobulin single chain scFvhl-VH-VH', anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], anti-[Homo sapiens ALB (albumin, human serum albumin, HSA)] and anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], trispecific
- immunoglobulin trispecific anti human cd3 antigen chain human mus musculus monoclonal hpn328 single chain variable fragment vh ggggs vl fusion protein with peptide linker ggggsgggs fusion protein with immunoglobulin anti human albumin human lama glama monoclonal hpn328 single domain vhh fragment fusion protein with peptide linker ggggsgggs fusion protein with immunoglobulin anti human notch ligand dll3 human lama glama monoclonal hpn328 single domain vhh fragment fusion protein with hexahistidine tag
- Immunoglobulin, trispecific, anti-(human CD3 antigen-chain) (human-Mus musculus monoclonal HPN328 single-chain variable fragment VH-(GGGGS)-VL) fusion protein with peptide linker (GGGGSGGGS) fusion protein with immunoglobulin anti-(human albumin) (human-Lama glama monoclonal HPN328 single-domain VHH fragment) fusion protein with peptide linker (GGGGSGGGS) fusion protein with immunoglobulin anti-(human Notch ligand DLL3) (human-Lama glama monoclonal HPN328 single-domain VHH fragment) fusion protein with hexahistidine tag
- tri specific t cell activating construct targeting dll3 hsa and cd3e
- Tri-specific T cell activating construct targeting DLL3, HSA, and CD3e
- CAS registry numbers
- 2851862-91-2
- ChEMBL ID
- CHEMBL6068123
- FDA ingredient codes (UNII)
- U6CKL88C8H
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mig
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVLGGGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSSGGGGSGGGSEVQLVESGGGLVQPGGSLTLSCAASSSSVSLLSLAWYRQAPGKKRELVAGISDDGSIVYMDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWITRSPYWGQGTLVTVSSHHHHHH
- Component
- Disulfide bridges
- Sequence
- 22-98 $ 162-230 $ 280-354 $ 404-477
Related records
Trials (3)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
In development for (1)
- Neoplasm Phase 2